GDF-8, widely known as Myostatin or MSTN, belongs to the transforming growth factor-beta (TGF-β) superfamily and functions as a potent endogenous negative regulator of skeletal muscle growth and development. It was first identified in 1997, and landmark animal studies demonstrated that knockout of the MSTN gene results in a dramatic “double-muscling” phenotype, characterized by drastically increased skeletal muscle mass. This discovery established GDF-8 as a core research target for muscle biology, muscle atrophy and degenerative muscle disease investigation.

Native GDF-8 is biosynthesized as a 375-amino-acid preproprotein precursor. This precursor undergoes multi-step enzymatic processing. The N-terminal signal peptide is cleaved first, followed by furin-like protease cleavage, separating the inhibitory N-terminal propeptide from the C-terminal mature domain. Two mature C-terminal monomers form a biologically active homodimer via intermolecular disulfide bond, featuring the classic cystine-knot structural fold typical of TGF-β family ligands. In circulation, the mature dimer remains non-covalently bound with its propeptide to form latent myostatin complex, which keeps the protein in an inactive state until local activation signals trigger dissociation.

Once activated, mature GDF-8 binds to ActRIIB serine/threonine kinase receptors on the surface of muscle satellite cells and myofibers. This binding initiates canonical Smad2/Smad3 intracellular signaling cascades, suppressing myogenic differentiation, inhibiting satellite cell proliferation and promoting muscle protein breakdown. The net biological outcome is limitation of muscle fiber hypertrophy and control of total muscle mass. Beyond skeletal muscle, GDF-8 also shows low-level expression in adipose tissue, cardiac muscle and kidney, expanding research directions into fat metabolism, cardiac remodeling and fibrosis mechanisms. It serves as an essential tool for exploring sarcopenia, muscular dystrophy, cachexia and age-related muscle wasting models. Researchers also use this recombinant protein to screen and validate myostatin antagonists, neutralizing antibodies, propeptide inhibitors and follistatin-related proteins.

Our recombinant human GDF-8 is expressed and purified from eukaryotic expression systems, which ensures correct protein folding and disulfide bond formation to retain native biological activity. The purification workflow consists of affinity chromatography, ion exchange chromatography and size-exclusion chromatography, effectively removing host cell residual proteins, genomic DNA and inactive misfolded aggregates. Each batch undergoes comprehensive quality control testing, including SDS-PAGE purity analysis, HPLC detection, endotoxin assay, bioactivity verification and visual appearance inspection. COA, SDS-PAGE image and activity assay reports can be provided for each shipment to satisfy strict laboratory documentation and audit standards. The lyophilization process stabilizes the protein tertiary structure, greatly reducing protein denaturation risk during international shipment and long-term frozen preservation. This product is supplied to university laboratories, biotech R&D institutes and preclinical research teams for skeletal muscle cell culture, myogenic differentiation experiments, muscle atrophy model construction, Smad signaling pathway research and inhibitor screening programs.